Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Allergan, Inc.    AGN

No quotes available
-- USD   0.00%
05/22 TEVA CFO : We'll close Allergan deal next month
05/22 ALLERGAN : Launches 'IBS-D on Tract,' New Online Resource to Support..
05/18 ALLERGAN : expansion approved for $13 million city tax deal, awaits ..
SummaryQuotesNewsCalendarCompanyFinancials 
News SummaryMost relevantAll newsSector news 

Allergan, Inc. : Allergan 3rd-Quarter Profit Edges Down; Weighs Options for Obesity Segment

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/30/2012 | 03:07pm CEST
   By Tess Stynes 
 

Allergan Inc.'s (AGN) third-quarter earnings edged down slightly as the maker of Botox and medical devices posted more one-time items, masking continued sales growth for top drug Botox.

Since the end of the quarter, Allergan said it is exploring strategic options for its obesity intervention business, including among other things, a potential sale of the unit.

For the year, the company raised the lower end of its guidance and now expects per-share earnings of $4.17 and $4.19 on product sales of $5.7 billion to $5.8 billion. Its prior view was for per-share profit of $4.15 to $4.19 and product sales of $5.65 billion to $5.8 billion.

For the current quarter, Allergan forecast per-share earnings of $1.18 to $1.20 on revenue of $1.47 billion to $1.55 billion. Analysts polled by Thomson Reuters most recently expected $1.20 and $1.51 billion, respectively.

Chief Executive David E.I. Pyott in August had commented that the company is watching carefully for signs of economic vulnerability, but doesn't see a threat to long-term goals. Allergan's cosmetic medical products seem to appeal to people with greater economic means and purchasing power, providing some shelter from economic turmoil, he said at the time.

Allergan reported a profit of $249.4 million, down from $249.8 million a year earlier. On a per-share basis, earnings were up at 82 cents from 81 cents amid fewer shares outstanding. Excluding acquisition and restructuring related charges and other items, earnings were up at $1.06 from 92 cents.

Revenue increased 6.4% to $1.41 billion. Product net sales were up 6.1% to $1.39 billion, and were up 9.4% excluding currency impacts.

The company in August forecast per-share earnings of $1.02 to $1.04 on revenue of $1.37 billion to $1.45 billion.

Gross margin rose to 86.7% from 85.8% amid the increased revenue.

Sales of Botox, which is used as a medical treatment and wrinkle-fighting cosmetic tool, rose 8.8% to $431.6 million.

Specialty pharmaceutical sales--which make up the bulk of Allergan's revenue-increased 8.1%, or roughly 11% excluding currency fluctuations.

Write to Tess Stynes at tess.stynes@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on ALLERGAN, INC.
05/22 TEVA CFO : We'll close Allergan deal next month
05/22 ALLERGAN : Launches 'IBS-D on Tract,' New Online Resource to Support Patients wi..
05/18 ALLERGAN : expansion approved for $13 million city tax deal, awaits $4 million c..
05/17 PFIZER : moves on from Allergan deal collapse with new $5.2bn takeover
05/16 Pfizer buying skin drug maker Anacor for $5.2 billion
05/16 Pfizer to buy eczema drugmaker Anacor for $5.2B
05/16 ALLERGAN : Reinforces Commitment to Hypertension Management with Four Poster Pre..
05/14 TEVA PHARMACEUTICAL : Can Teva Pharmaceutical Industries Ltd (ADR) Survive Gener..
05/14 Baupost took $461 million Allergan stake before Pfizer deal collapsed
05/13 S&P 500 MOVERS : Jwn, nvda
Advertisement
Income Statement Evolution
More Financials